[Featured Stock] Barunson Rises for 2 Consecutive Days on Moderna Vaccine Development Hopes...

[Asia Economy Reporter Minji Lee] Barunson has been on the rise for two consecutive days amid expectations for the development of a novel coronavirus (COVID-19) vaccine.

At 9:13 AM on the 16th in the KOSDAQ market, Barunson was trading at 3,405 KRW, up 19% from the previous session. Barunson also ended the previous day at the upper price limit. At the same time, Barunson E&A is also showing an increase of about 2.5%.

On March 20, Barunson purchased 21,000 shares of Moderna, listed on the US NASDAQ market, for 786.35 million KRW. Moderna recently succeeded in antibody formation in all subjects during clinical trials for COVID-19 vaccine development and is approaching Phase 3, the final stage of new drug development clinical trials.

This content was produced with the assistance of AI translation services.